Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Nurtec ODT
Synonyms :
rimegepant
Class :
Antimigraine Agents; CGRP Receptor Antagonists
Dosage forms & Strengths:Â
Adult:Â
Oral Disintegrating tabletÂ
75 mgÂ
75 mg orally as needed
75 mg orally every other day
Safety and efficacy are not seen in pediatricsÂ
Safety and efficacy are not seen in pediatrics.
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of glycoprotein Inhibitors
may enhance the serum concentration of P-glycoprotein inhibitors
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance the effect when combined with tafamidis meglumine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rimegepant
both the drugs, when used in combination, increase the effect of one another
regorafenib, when used in combination with rimegepant, increases the impact or level of each other
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
it increases the concentration of OATP1B1/1B3 substrates in the serum
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
1-10%:Â
NauseaÂ
<1%:Â
Severe rashÂ
HypersensitivityÂ
Rimegepant is contraindicated in patients hypersensitive to the active ingredient.Â
Pregnancy consideration:Â Â
Insufficient data is available regarding the use of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the secretion of the drug in breast milk.Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: rimegepantÂ
Pronounced: rime-gep-antÂ
Why do we use rimegepant?Â
Rimegepant helps to prevent and treat migraine.Â